FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2200529412> ?p ?o ?g. }

• W2200529412 endingPage "10" @default.
• W2200529412 startingPage "1" @default.
• W2200529412 abstract "Acquired aplastic anemia (aAA) results from the T cell-mediated autoimmune destruction of hematopoietic stem cells. Factors predicting response to immune suppression therapy (IST) or development of myelodysplastic syndrome (MDS) are beginning to be elucidated. Our recent data suggest most patients with aAA treated with IST develop clonal somatic genetic alterations in hematopoietic cells. One frequent acquired abnormality is copy-number neutral loss of heterozygosity on chromosome 6p (6p CN-LOH) involving the human leukocyte antigen (HLA) locus. We hypothesized that because 6p CN-LOH clones may arise from selective pressure to escape immune surveillance through deletion of HLA alleles, the development of 6p CN-LOH may affect response to IST. We used single nucleotide polymorphism array genotyping and targeted next-generation sequencing of HLA alleles to assess frequency of 6p CN-LOH, identity of HLA alleles lost through 6p CN-LOH, and impact of 6p CN-LOH on response to IST. 6p CN-LOH clones were present in 11.3% of patients, remained stable over time, and were not associated with development of MDS-defining cytogenetic abnormalities. Notably, no patient with 6p CN-LOH treated with IST achieved a complete response. In summary, clonal 6p CN-LOH in aAA defines a unique subgroup of patients that may provide insights into hematopoietic clonal evolution. Acquired aplastic anemia (aAA) results from the T cell-mediated autoimmune destruction of hematopoietic stem cells. Factors predicting response to immune suppression therapy (IST) or development of myelodysplastic syndrome (MDS) are beginning to be elucidated. Our recent data suggest most patients with aAA treated with IST develop clonal somatic genetic alterations in hematopoietic cells. One frequent acquired abnormality is copy-number neutral loss of heterozygosity on chromosome 6p (6p CN-LOH) involving the human leukocyte antigen (HLA) locus. We hypothesized that because 6p CN-LOH clones may arise from selective pressure to escape immune surveillance through deletion of HLA alleles, the development of 6p CN-LOH may affect response to IST. We used single nucleotide polymorphism array genotyping and targeted next-generation sequencing of HLA alleles to assess frequency of 6p CN-LOH, identity of HLA alleles lost through 6p CN-LOH, and impact of 6p CN-LOH on response to IST. 6p CN-LOH clones were present in 11.3% of patients, remained stable over time, and were not associated with development of MDS-defining cytogenetic abnormalities. Notably, no patient with 6p CN-LOH treated with IST achieved a complete response. In summary, clonal 6p CN-LOH in aAA defines a unique subgroup of patients that may provide insights into hematopoietic clonal evolution." @default.
• W2200529412 created "2016-06-24" @default.
• W2200529412 creator A5004217093 @default.
• W2200529412 creator A5007709288 @default.
• W2200529412 creator A5008935118 @default.
• W2200529412 creator A5013634966 @default.
• W2200529412 creator A5014999980 @default.
• W2200529412 creator A5017202683 @default.
• W2200529412 creator A5023572421 @default.
• W2200529412 creator A5028407759 @default.
• W2200529412 creator A5058020526 @default.
• W2200529412 creator A5070139236 @default.
• W2200529412 creator A5072539940 @default.
• W2200529412 creator A5081106729 @default.
• W2200529412 creator A5083062306 @default.
• W2200529412 date "2016-01-01" @default.
• W2200529412 modified "2023-10-18" @default.
• W2200529412 title "Clonal evolution and clinical significance of copy number neutral loss of heterozygosity of chromosome arm 6p in acquired aplastic anemia" @default.
• W2200529412 cites W15191073 @default.
• W2200529412 cites W1966149362 @default.
• W2200529412 cites W1983356999 @default.
• W2200529412 cites W1997651943 @default.
• W2200529412 cites W2015881261 @default.
• W2200529412 cites W2033594330 @default.
• W2200529412 cites W2033654955 @default.
• W2200529412 cites W2033884448 @default.
• W2200529412 cites W2036245297 @default.
• W2200529412 cites W2052285621 @default.
• W2200529412 cites W2074604345 @default.
• W2200529412 cites W2076506261 @default.
• W2200529412 cites W2076630716 @default.
• W2200529412 cites W2079751470 @default.
• W2200529412 cites W2091290287 @default.
• W2200529412 cites W2102187103 @default.
• W2200529412 cites W2102943057 @default.
• W2200529412 cites W2105159677 @default.
• W2200529412 cites W2108249391 @default.
• W2200529412 cites W2120306804 @default.
• W2200529412 cites W2123133345 @default.
• W2200529412 cites W2165057682 @default.
• W2200529412 cites W2319873259 @default.
• W2200529412 cites W783150221 @default.
• W2200529412 doi "https://doi.org/10.1016/j.cancergen.2015.10.002" @default.
• W2200529412 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4738084" @default.
• W2200529412 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26702937" @default.
• W2200529412 hasPublicationYear "2016" @default.
• W2200529412 type Work @default.
• W2200529412 sameAs 2200529412 @default.
• W2200529412 citedByCount "32" @default.
• W2200529412 countsByYear W22005294122015 @default.
• W2200529412 countsByYear W22005294122016 @default.
• W2200529412 countsByYear W22005294122017 @default.
• W2200529412 countsByYear W22005294122018 @default.
• W2200529412 countsByYear W22005294122019 @default.
• W2200529412 countsByYear W22005294122020 @default.
• W2200529412 countsByYear W22005294122021 @default.
• W2200529412 countsByYear W22005294122022 @default.
• W2200529412 countsByYear W22005294122023 @default.
• W2200529412 crossrefType "journal-article" @default.
• W2200529412 hasAuthorship W2200529412A5004217093 @default.
• W2200529412 hasAuthorship W2200529412A5007709288 @default.
• W2200529412 hasAuthorship W2200529412A5008935118 @default.
• W2200529412 hasAuthorship W2200529412A5013634966 @default.
• W2200529412 hasAuthorship W2200529412A5014999980 @default.
• W2200529412 hasAuthorship W2200529412A5017202683 @default.
• W2200529412 hasAuthorship W2200529412A5023572421 @default.
• W2200529412 hasAuthorship W2200529412A5028407759 @default.
• W2200529412 hasAuthorship W2200529412A5058020526 @default.
• W2200529412 hasAuthorship W2200529412A5070139236 @default.
• W2200529412 hasAuthorship W2200529412A5072539940 @default.
• W2200529412 hasAuthorship W2200529412A5081106729 @default.
• W2200529412 hasAuthorship W2200529412A5083062306 @default.
• W2200529412 hasBestOaLocation W22005294122 @default.
• W2200529412 hasConcept C104317684 @default.
• W2200529412 hasConcept C113968399 @default.
• W2200529412 hasConcept C121608353 @default.
• W2200529412 hasConcept C143589142 @default.
• W2200529412 hasConcept C147483822 @default.
• W2200529412 hasConcept C180754005 @default.
• W2200529412 hasConcept C188280979 @default.
• W2200529412 hasConcept C203014093 @default.
• W2200529412 hasConcept C2780007613 @default.
• W2200529412 hasConcept C2780817109 @default.
• W2200529412 hasConcept C2781440808 @default.
• W2200529412 hasConcept C502942594 @default.
• W2200529412 hasConcept C54355233 @default.
• W2200529412 hasConcept C86803240 @default.
• W2200529412 hasConceptScore W2200529412C104317684 @default.
• W2200529412 hasConceptScore W2200529412C113968399 @default.
• W2200529412 hasConceptScore W2200529412C121608353 @default.
• W2200529412 hasConceptScore W2200529412C143589142 @default.
• W2200529412 hasConceptScore W2200529412C147483822 @default.
• W2200529412 hasConceptScore W2200529412C180754005 @default.
• W2200529412 hasConceptScore W2200529412C188280979 @default.
• W2200529412 hasConceptScore W2200529412C203014093 @default.
• W2200529412 hasConceptScore W2200529412C2780007613 @default.
• W2200529412 hasConceptScore W2200529412C2780817109 @default.
• W2200529412 hasConceptScore W2200529412C2781440808 @default.

• next